Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMU-132-06 Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
2023-508302-24-00Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- May 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of sacituzumab govitecan in transitional cell carcinoma (TCC) (7 cohorts), sponsored by Gilead Sciences. Primary endpoints: Objective Response Rate (ORR) - Cohorts 1 and 2, Objective Response Rate (ORR) - Cohorts 3 and 4 and 3 more. Planned start May 2019; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-508302-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508302-24-00.